Originally published as JCO Early Release 10.1200/JCO.2005.10.192 on March 14 2005
Journal of Clinical Oncology, Vol 23, No 18 (June 20), 2005: pp. 4063-4069
© 2005 American Society of Clinical Oncology.
Randomized Placebo-Controlled Study of Low-Dose Warfarin for the Prevention of Central Venous CatheterAssociated Thrombosis in Patients With Cancer
Stephen Couban,
Michael Goodyear,
Margot Burnell,
Sean Dolan,
Parveen Wasi,
David Barnes,
Darlene MacLeod,
Erica Burton,
Pantelis Andreou,
David R. Anderson
From the Departments of Medicine, Community Health and Epidemiology, and Radiology, Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia; Department of Oncology, Saint John Regional Hospital, Saint John, New Brunswick; and Department of Medicine, McMaster University, Hamilton, Ontario, Canada
Address reprint requests to Stephen Couban, MD, Department of Medicine, Queen Elizabeth II Health Sciences Centre, Room 417, Bethune Bldg, 1278 Tower Rd, Halifax, Nova Scotia B3H 2Y9, Canada; e-mail: stephen.couban{at}cdha.nshealth.ca
PURPOSE: In this multicenter, randomized, placebo-controlled clinical trial, we studied whether warfarin 1 mg daily reduces the incidence of symptomatic central venous catheter (CVC) associated thrombosis in patients with cancer.
PATIENTS AND METHODS: Two hundred fifty-five patients with cancer who required a CVC for at least 7 days were randomly assigned to receive warfarin 1 mg or placebo.
RESULTS: There were 11 (4.3%) symptomatic CVC-associated thromboses among 255 patients, with no difference in the incidence of symptomatic CVC-associated thrombosis between patients taking warfarin 1 mg daily (six of 130 patients; 4.6%) and patients taking placebo (five of 125 patients; 4.0%; hazard ratio, 1.20; 95% CI, 0.37 to 3.94). Warfarin had no effect on CVC life span (84 days v 63 days in control and warfarin groups, respectively; 95% confidence limit, 16 to 55 days; P = .09), and it did not affect the number of premature CVC removals (23.2% v 25.4% in control and warfarin groups, respectively; 95% confidence limit of difference 8.34 to 12.71; P = .68) or the frequency of major bleeding episodes (2% v 0% in control and warfarin groups, respectively; P = .5, Fisher's exact test).
CONCLUSION: Symptomatic CVC-associated thrombosis in patients with cancer, although significant, is less common than previously reported. In this study, the administration of warfarin 1 mg daily did not reduce the incidence of symptomatic CVC-associated thrombosis in patients with cancer. However, the low rate of symptomatic CVC-associated thrombosis means that a much larger trial is required to address this issue definitively.
Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
Related Editorial
- Catheter-Associated Thrombosis: Thromboprophylaxis or Not?
M. Levine and A.K. Kakkar
JCO 2005 23: 4006-4008
[Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
M. De Cicco, M. Matovic, L. Balestreri, A. Steffan, R. Pacenzia, M. Malafronte, D. Fantin, C. A. Bertuzzi, F. Fabiani, S. Morassut, et al.
Early and short-term acenocumarine or dalteparin for the prevention of central vein catheter-related thrombosis in cancer patients: a randomized controlled study based on serial venographies
Ann. Onc.,
December 1, 2009;
20(12):
1936 - 1942.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. I. Zwicker, H. A. Liebman, D. Neuberg, R. Lacroix, K. A. Bauer, B. C. Furie, and B. Furie
Tumor-Derived Tissue Factor-Bearing Microparticles Are Associated With Venous Thromboembolic Events in Malignancy
Clin. Cancer Res.,
November 15, 2009;
15(22):
6830 - 6840.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. A. Khorana, M. B. Streiff, D. Farge, M. Mandala, P. Debourdeau, F. Cajfinger, M. Marty, A. Falanga, and G. H. Lyman
Venous Thromboembolism Prophylaxis and Treatment in Cancer: A Consensus Statement of Major Guidelines Panels and Call to Action
J. Clin. Oncol.,
October 10, 2009;
27(29):
4919 - 4926.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. A. Khorana and G. C. Connolly
Assessing Risk of Venous Thromboembolism in the Patient With Cancer
J. Clin. Oncol.,
October 10, 2009;
27(29):
4839 - 4847.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. P. Shivakumar, D. R. Anderson, and S. Couban
Catheter-Associated Thrombosis in Patients With Malignancy
J. Clin. Oncol.,
October 10, 2009;
27(29):
4858 - 4864.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Falanga and M. Marchetti
Venous Thromboembolism in the Hematologic Malignancies
J. Clin. Oncol.,
October 10, 2009;
27(29):
4848 - 4857.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Rana and M. N. Levine
Prevention of Thrombosis in Ambulatory Patients With Cancer
J. Clin. Oncol.,
October 10, 2009;
27(29):
4885 - 4888.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. A. Khorana
Cancer and thrombosis: implications of published guidelines for clinical practice
Ann. Onc.,
October 1, 2009;
20(10):
1619 - 1630.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Debourdeau, D. Kassab Chahmi, G. Le Gal, I. Kriegel, E. Desruennes, M.-C. Douard, I. Elalamy, G. Meyer, P. Mismetti, M. Pavic, et al.
2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group
Ann. Onc.,
September 1, 2009;
20(9):
1459 - 1471.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Starling, S. Rao, D. Cunningham, T. Iveson, M. Nicolson, F. Coxon, G. Middleton, F. Daniel, J. Oates, and A. R. Norman
Thromboembolism in Patients With Advanced Gastroesophageal Cancer Treated With Anthracycline, Platinum, and Fluoropyrimidine Combination Chemotherapy: A Report From the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group
J. Clin. Oncol.,
August 10, 2009;
27(23):
3786 - 3793.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. A. Khorana and G. H. Lyman
Incidence and Prevention of Cancer-associated Thrombosis
ASCO Educational Book,
January 1, 2009;
2009(1):
321 - 325.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N Walji, A K Chan, and D R Peake
Common acute oncological emergencies: diagnosis, investigation and management
Postgrad. Med. J.,
August 1, 2008;
84(994):
418 - 427.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. E. Gerber, J. B. Segal, M. Y. Levy, J. Kane, R. J. Jones, and M. B. Streiff
The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention
Blood,
August 1, 2008;
112(3):
504 - 510.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. H. Geerts, D. Bergqvist, G. F. Pineo, J. A. Heit, C. M. Samama, M. R. Lassen, and C. W. Colwell
Prevention of Venous Thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest,
June 1, 2008;
133(6_suppl):
381S - 453S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. A. Khorana, N. M. Kuderer, E. Culakova, G. H. Lyman, and C. W. Francis
Development and validation of a predictive model for chemotherapy-associated thrombosis
Blood,
May 15, 2008;
111(10):
4902 - 4907.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. S. Boersma, K.-S. G. Jie, A. Verbon, E. C. M. van Pampus, and H. C. Schouten
Thrombotic and infectious complications of central venous catheters in patients with hematological malignancies
Ann. Onc.,
March 1, 2008;
19(3):
433 - 442.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Vescia, A. K. Baumgartner, V. R. Jacobs, M. Kiechle-Bahat, A. Rody, S. Loibl, and N. Harbeck
Management of venous port systems in oncology: a review of current evidence
Ann. Onc.,
January 1, 2008;
19(1):
9 - 15.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. J. Munoz, P. Mismetti, R. Poggio, R. Valle, M. Barron, M. Guil, M. Monreal, and for the RIETE Investigators
Clinical Outcome of Patients With Upper-Extremity Deep Vein Thrombosis: Results From the RIETE Registry,{dagger}
Chest,
January 1, 2008;
133(1):
143 - 148.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Falanga, A. Y. Y. Lee, M. B. Streiff, and G. H. Lyman
Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer
ASCO Educational Book,
January 1, 2008;
2008(1):
258 - 268.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. A. Spencer, D. Lessard, C. Emery, G. Reed, and R. J. Goldberg
Venous Thromboembolism in the Outpatient Setting
Arch Intern Med,
July 23, 2007;
167(14):
1471 - 1475.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D Fagnani, R Franchi, C Porta, P Pugliese, K Borgonovo, A Bertolini, M Duro, A Ardizzoia, V Filipazzi, L Isa, et al.
Thrombosis-related complications and mortality in cancer patients with central venous devices: an observational study on the effect of antithrombotic prophylaxis
Ann. Onc.,
March 1, 2007;
18(3):
551 - 555.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. C. Kwaan
Double Hazard of Thrombophilia and Bleeding in Leukemia
Hematology,
January 1, 2007;
2007(1):
151 - 157.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Falanga and F. R. Rickles
Management of Thrombohemorrhagic Syndromes (THS) in Hematologic Malignancies
Hematology,
January 1, 2007;
2007(1):
165 - 171.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Gaitini, N. Beck-Razi, N. Haim, and B. Brenner
Prevalence of Upper Extremity Deep Venous Thrombosis Diagnosed by Color Doppler Duplex Sonography in Cancer Patients With Central Venous Catheters.
J. Ultrasound Med.,
October 1, 2006;
25(10):
1297 - 1303.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A Fennerty
Venous thromboembolic disease and cancer.
Postgrad. Med. J.,
October 1, 2006;
82(972):
642 - 648.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Y.Y. Lee, M. N. Levine, G. Butler, C. Webb, L. Costantini, C. Gu, and J. A. Julian
Incidence, Risk Factors, and Outcomes of Catheter-Related Thrombosis in Adult Patients With Cancer
J. Clin. Oncol.,
March 20, 2006;
24(9):
1404 - 1408.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Thromboembolism after pneumonectomy for malignancy: An independent marker of poor outcome.
J. Thorac. Cardiovasc. Surg.,
March 1, 2006;
131(3):
711 - 718.
|
 |
|

|
 |

|
 |
 
G. Ferretti, E. Bria, A. Felici, P. Carlini, D. Giannarelli, M. Ciccarese, P. Papaldo, A. Fabi, A. Gelibter, and F. Cognetti
Catheter-associated thrombosis: thromboprophylaxis for cancer patients who carry factor V Leiden?
Ann. Onc.,
March 1, 2006;
17(3):
528 - 529.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Karthaus, A. Kretzschmar, H. Kroning, M. Biakhov, D. Irwin, N. Marschner, C. Slabber, G. Fountzilas, A. Garin, N. G. F. Abecasis, et al.
Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial
Ann. Onc.,
February 1, 2006;
17(2):
289 - 296.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Magagnoli, G. Masci, L. Castagna, E. Morenghi, and A. Santoro
High incidence of INR alteration in gastrointestinal cancer patients treated with mini-dose warfarin and 5-fluorouracil-based regimens
Ann. Onc.,
January 1, 2006;
17(1):
174 - 176.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. A. Krzywda and D. A. Andris
Twenty-five Years of Advances in Vascular Access: Bridging Research to Clinical Practice
Nutr Clin Pract,
December 1, 2005;
20(6):
597 - 606.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Curigliano, M. Colleoni, M. Mandala, T. De Pas, G. Spitaleri, F. de Braud, and A. Goldhirsch
Prophylaxis for Venous Thromboembolism in Cancer Patients With a Central Vein Catheter: New Tones for an Old Song
J. Clin. Oncol.,
October 1, 2005;
23(28):
7243 - 7244.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Levine and A.K. Kakkar
Catheter-Associated Thrombosis: Thromboprophylaxis or Not?
J. Clin. Oncol.,
June 20, 2005;
23(18):
4006 - 4008.
[Full Text]
[PDF]
|
 |
|
|